← Back to Search

Proteasome Inhibitor

Mezigdomide + Carfilzomib + Dexamethasone for Multiple Myeloma (SUCCESSOR-2 Trial)

Phase 3
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 5 years
Awards & highlights

Summary

This trial is testing a new drug called Mezigdomide combined with two other drugs to treat patients whose blood cancer has come back or not responded to previous treatments. The new drug aims to stop cancer cells from growing and spreading.

Who is the study for?
This trial is for individuals with multiple myeloma who've had at least one prior treatment, including lenalidomide and an anti-CD38 monoclonal antibody. They should have shown some response to previous treatments and must have disease progression after the last regimen. Those previously treated with mezigdomide or carfilzomib, or recent stem cell transplant recipients cannot participate.
What is being tested?
The SUCCESSOR-2 study is testing Mezigdomide combined with Carfilzomib and Dexamethasone (MeziKD) against just Carfilzomib and Dexamethasone (Kd). The goal is to see which combination works better for relapsed or refractory multiple myeloma.
What are the potential side effects?
Potential side effects include immune system suppression leading to infections, blood clots, fatigue, nausea, diarrhea, muscle pain, fever from infusion reactions. Long-term risks may involve bone marrow suppression causing anemia or bleeding problems.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Change From Baseline in the European Organization for Research and Treatment of Cancer - Quality of Life C30 Questionnaire (EORTC QLQ-C30)
Change From Baseline in the European Quality of Life Multiple Myeloma Module (EORTC QLQ-MY20)
Complete Response (CR) Or Better (CRR)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MeziKd (Mezigdomide + Carfilzomib + Dexamethasone)Experimental Treatment3 Interventions
Group II: Kd (Carfilzomib + Dexamethasone)Active Control2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
2007
Completed Phase 4
~2650
Mezigdomide
2023
Completed Phase 1
~40
Carfilzomib
2017
Completed Phase 3
~1430

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Multiple Myeloma include immunomodulatory drugs (IMiDs) like Mezigdomide, proteasome inhibitors, and monoclonal antibodies. IMiDs induce apoptosis in myeloma cells and enhance the immune system's ability to target these cells. Proteasome inhibitors, such as carfilzomib, disrupt protein degradation in cancer cells, leading to cell death. Monoclonal antibodies, like daratumumab, specifically target antigens on myeloma cells, facilitating their destruction by the immune system. These mechanisms are crucial as they offer multiple pathways to attack myeloma cells, improving treatment efficacy and patient outcomes.
Experimental approaches in the treatment of multiple myeloma.

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,680 Previous Clinical Trials
4,124,904 Total Patients Enrolled
90 Trials studying Multiple Myeloma
21,903 Patients Enrolled for Multiple Myeloma

Media Library

Carfilzomib (Proteasome Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05552976 — Phase 3
Multiple Myeloma Research Study Groups: MeziKd (Mezigdomide + Carfilzomib + Dexamethasone), Kd (Carfilzomib + Dexamethasone)
Multiple Myeloma Clinical Trial 2023: Carfilzomib Highlights & Side Effects. Trial Name: NCT05552976 — Phase 3
Carfilzomib (Proteasome Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05552976 — Phase 3
~219 spots leftby Feb 2026